Efficacy of azithromycin for treating Babesia microti infection in the hamster model

Louis M. Weiss, Louis M. Weiss, Scott Wasserman, Helieh S. Oz, James Retsema, Herbert B. Tanowitz

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Because of its prevalence and severity, Babesia microti infection is an important public health problem. The current treatment of choice is clindamycin plus quinine. However, in some cases other treatments are needed because of drug intolerance or relapse. The activity of azithromycin was investigated for treatment of babesiosis in the hamster model. All animals received vancomycin to prevent antibiotic-associated colitis. Quinine (250 mg/kg/day), azithromycin (150 mg/kg/ day), and the combination of azithromycin and quinine were compared. A significant suppression of parasitemia was found in all treatment groups (combination had the greatest effect, followed by azithromycin, then quinine; P < .05). The mean survival was significantly prolonged in the combination group (P < .05). Azithromycin as monotherapy in a higher dose (300 mg/kg/ day) also resulted in a significant prolongation of survival (P < .05). Spirogermanium and cipro-floxacin, which have been reported to have antimalarial activity, had no effect on parasitemia or survival in this experimental babesiosis model.

Original languageEnglish (US)
Pages (from-to)1289-1292
Number of pages4
JournalJournal of Infectious Diseases
Volume168
Issue number5
StatePublished - Nov 1993

Fingerprint

Babesia microti
Azithromycin
Cricetinae
Quinine
Babesiosis
Infection
Parasitemia
spirogermanium
Pseudomembranous Enterocolitis
Clindamycin
Antimalarials
Vancomycin
Ciprofloxacin
Theoretical Models
Public Health
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Weiss, L. M., Weiss, L. M., Wasserman, S., Oz, H. S., Retsema, J., & Tanowitz, H. B. (1993). Efficacy of azithromycin for treating Babesia microti infection in the hamster model. Journal of Infectious Diseases, 168(5), 1289-1292.

Efficacy of azithromycin for treating Babesia microti infection in the hamster model. / Weiss, Louis M.; Weiss, Louis M.; Wasserman, Scott; Oz, Helieh S.; Retsema, James; Tanowitz, Herbert B.

In: Journal of Infectious Diseases, Vol. 168, No. 5, 11.1993, p. 1289-1292.

Research output: Contribution to journalArticle

Weiss, LM, Weiss, LM, Wasserman, S, Oz, HS, Retsema, J & Tanowitz, HB 1993, 'Efficacy of azithromycin for treating Babesia microti infection in the hamster model', Journal of Infectious Diseases, vol. 168, no. 5, pp. 1289-1292.
Weiss LM, Weiss LM, Wasserman S, Oz HS, Retsema J, Tanowitz HB. Efficacy of azithromycin for treating Babesia microti infection in the hamster model. Journal of Infectious Diseases. 1993 Nov;168(5):1289-1292.
Weiss, Louis M. ; Weiss, Louis M. ; Wasserman, Scott ; Oz, Helieh S. ; Retsema, James ; Tanowitz, Herbert B. / Efficacy of azithromycin for treating Babesia microti infection in the hamster model. In: Journal of Infectious Diseases. 1993 ; Vol. 168, No. 5. pp. 1289-1292.
@article{d87eac18986e4e929f87b1ca968eee7f,
title = "Efficacy of azithromycin for treating Babesia microti infection in the hamster model",
abstract = "Because of its prevalence and severity, Babesia microti infection is an important public health problem. The current treatment of choice is clindamycin plus quinine. However, in some cases other treatments are needed because of drug intolerance or relapse. The activity of azithromycin was investigated for treatment of babesiosis in the hamster model. All animals received vancomycin to prevent antibiotic-associated colitis. Quinine (250 mg/kg/day), azithromycin (150 mg/kg/ day), and the combination of azithromycin and quinine were compared. A significant suppression of parasitemia was found in all treatment groups (combination had the greatest effect, followed by azithromycin, then quinine; P < .05). The mean survival was significantly prolonged in the combination group (P < .05). Azithromycin as monotherapy in a higher dose (300 mg/kg/ day) also resulted in a significant prolongation of survival (P < .05). Spirogermanium and cipro-floxacin, which have been reported to have antimalarial activity, had no effect on parasitemia or survival in this experimental babesiosis model.",
author = "Weiss, {Louis M.} and Weiss, {Louis M.} and Scott Wasserman and Oz, {Helieh S.} and James Retsema and Tanowitz, {Herbert B.}",
year = "1993",
month = "11",
language = "English (US)",
volume = "168",
pages = "1289--1292",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Efficacy of azithromycin for treating Babesia microti infection in the hamster model

AU - Weiss, Louis M.

AU - Weiss, Louis M.

AU - Wasserman, Scott

AU - Oz, Helieh S.

AU - Retsema, James

AU - Tanowitz, Herbert B.

PY - 1993/11

Y1 - 1993/11

N2 - Because of its prevalence and severity, Babesia microti infection is an important public health problem. The current treatment of choice is clindamycin plus quinine. However, in some cases other treatments are needed because of drug intolerance or relapse. The activity of azithromycin was investigated for treatment of babesiosis in the hamster model. All animals received vancomycin to prevent antibiotic-associated colitis. Quinine (250 mg/kg/day), azithromycin (150 mg/kg/ day), and the combination of azithromycin and quinine were compared. A significant suppression of parasitemia was found in all treatment groups (combination had the greatest effect, followed by azithromycin, then quinine; P < .05). The mean survival was significantly prolonged in the combination group (P < .05). Azithromycin as monotherapy in a higher dose (300 mg/kg/ day) also resulted in a significant prolongation of survival (P < .05). Spirogermanium and cipro-floxacin, which have been reported to have antimalarial activity, had no effect on parasitemia or survival in this experimental babesiosis model.

AB - Because of its prevalence and severity, Babesia microti infection is an important public health problem. The current treatment of choice is clindamycin plus quinine. However, in some cases other treatments are needed because of drug intolerance or relapse. The activity of azithromycin was investigated for treatment of babesiosis in the hamster model. All animals received vancomycin to prevent antibiotic-associated colitis. Quinine (250 mg/kg/day), azithromycin (150 mg/kg/ day), and the combination of azithromycin and quinine were compared. A significant suppression of parasitemia was found in all treatment groups (combination had the greatest effect, followed by azithromycin, then quinine; P < .05). The mean survival was significantly prolonged in the combination group (P < .05). Azithromycin as monotherapy in a higher dose (300 mg/kg/ day) also resulted in a significant prolongation of survival (P < .05). Spirogermanium and cipro-floxacin, which have been reported to have antimalarial activity, had no effect on parasitemia or survival in this experimental babesiosis model.

UR - http://www.scopus.com/inward/record.url?scp=0027378104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027378104&partnerID=8YFLogxK

M3 - Article

VL - 168

SP - 1289

EP - 1292

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -